The ACD setting of Hu2G10, namely LCB84, demonstrated potent effectiveness against multiple Trop2-positive cell-line derived xenograft (CDX) models, including triple-negative breast cancer (TNBC), pancreatic ductal adenocarcinoma (PDAC), GC and NSCLC (59). This evidence concerns the gene TACSTD2 and non-small cell lung carcinoma.